Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Share-based Compensation: 2020-2025

Historic Share-based Compensation for InMed Pharmaceuticals (INM) over the last 6 years, with Jun 2025 value amounting to $119,307.

  • InMed Pharmaceuticals' Share-based Compensation fell 30.24% to $20,205 in Q3 2025 from the same period last year, while for Sep 2025 it was $110,547, marking a year-over-year decrease of 21.87%. This contributed to the annual value of $119,307 for FY2025, which is 13.37% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Share-based Compensation stood at $119,307 for FY2025, which was down 13.37% from $137,714 recorded in FY2024.
  • InMed Pharmaceuticals' Share-based Compensation's 5-year high stood at $697,894 during FY2022, with a 5-year trough of $119,307 in FY2025.
  • Moreover, its 3-year median value for Share-based Compensation was $137,714 (2024), whereas its average is $178,392.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Share-based Compensation grew by 14.37% in 2022, and later tumbled by 60.14% in 2023.
  • Yearly analysis of 5 years shows InMed Pharmaceuticals' Share-based Compensation stood at $610,193 in 2021, then rose by 14.37% to $697,894 in 2022, then plummeted by 60.14% to $278,155 in 2023, then crashed by 50.49% to $137,714 in 2024, then decreased by 13.37% to $119,307 in 2025.